Marshall Wace’s ImmunityBio IBRX Stock Holding History

Marshall Wace’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Buy	18,800 +6,000	+47%	+$45.4K	﹤0.01%	2858
2026 Q1	$98.2K	Buy	+12,800	New	+$87.6K	﹤0.01%	2903

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's IBRX Position: Q2 2026 in Review

Marshall Wace increased its ImmunityBio (IBRX) stake by 403% in Q2 2026, buying an estimated $2.35M and bringing the position to 387,700 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

Marshall Wace first reported a position in IBRX in Q4 2021 and has held it in 9 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Marshall Wace held 387,700 shares of ImmunityBio worth $3.4M as of Q2 2026.
Marshall Wace bought 310,675 ImmunityBio shares in Q2 2026, an estimated $2.35M.
ImmunityBio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1568 holding.
Marshall Wace first reported a position in ImmunityBio in Q4 2021 and has held it in 9 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.